futibatinib, fulvestrant

PreclinicalSmall molecule

futibatinib, fulvestrant is one of 2 small molecule programs targeting Advanced/Metastatic Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced/metastatic CancerActive, not recruiting

Advanced/metastatic CancerPreclinical

Active, not recruiting

Competition

Competitive Landscape

2 competitors in Advanced/metastatic Cancer

#DrugCompanyPhaseTrials

Lytgobi

Taiho Oncology, Inc.

Preclinical

1 2

futibatinib, fulvestrant

Taiho Oncology, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

PreclinicalActive, not recruiting

Advanced/metastatic Cancer

NCT06506955

Clinical

Trials by Indication[1]

Advanced/Metastatic Cancer1 trial

An Open-label, Rollover Study of Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib Study

Active, not recruiting· Taiho Oncology, Inc. logo

Taiho Oncology, Inc.·Preclinical·NCT06506955·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for futibatinib, fulvestrant. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — futibatinib, fulvestrant compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for futibatinib, fulvestrant. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Taiho Oncology, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Taiho Oncology, Inc.

futibatinib, fulvestrant

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Advanced/Metastatic Cancer1 trial

References

Drug Info

Quick Facts

Related News